PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a provider of biomedical therapeutics for animals, was featured in the Sight & Sound's Visionaries Series on Bloomberg Television. The episode highlighted Spryng™ with OsteoCushion™ Technology, PetVivo's flagship product for managing osteoarthritis and other musculoskeletal conditions in animals. The program aired on September 5 and was distributed across various digital platforms, reaching a wide audience.
PetVivo CEO John Lai emphasized the transformative impact of Spryng on animal joint health. The company has achieved significant milestones, with Spryng now used in over 800 veterinary clinics across 50 states, resulting in the distribution of more than 10,000 Spryng syringes nationwide since its commercialization. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), un fornitore di terapie biomediche per animali, è stato presentato nella Visionaries Series della rivista Sight & Sound su Bloomberg Television. L'episodio ha messo in evidenza Spryng™ con la Tecnologia OsteoCushion™, il prodotto di punta di PetVivo per la gestione dell'osteoartrite e di altre condizioni muscoloscheletriche negli animali. Il programma è andato in onda il 5 settembre ed è stato distribuito su varie piattaforme digitali, raggiungendo un vasto pubblico.
Il CEO di PetVivo, John Lai, ha sottolineato l'impatto trasformativo di Spryng sulla salute articolare degli animali. L'azienda ha raggiunto traguardi significativi, con Spryng utilizzato in oltre 800 cliniche veterinarie in 50 stati, portando alla distribuzione di più di 10.000 siringhe di Spryng a livello nazionale dalla sua commercializzazione. Questo successo è in linea con la crescita prevista del mercato della salute animale negli Stati Uniti, che si prevede raggiunga un valore di $11,3 miliardi entro il 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), un proveedor de terapias biomédicas para animales, fue destacado en la serie Visionaries de Sight & Sound en Bloomberg Television. El episodio destacó Spryng™ con Tecnología OsteoCushion™, el producto insignia de PetVivo para el manejo de la osteoartritis y otras condiciones musculoesqueléticas en animales. El programa se emitió el 5 de septiembre y se distribuyó a través de varias plataformas digitales, alcanzando una amplia audiencia.
El CEO de PetVivo, John Lai, enfatizó el impacto transformador de Spryng en la salud articular de los animales. La empresa ha logrado hitos significativos, con Spryng utilizado en más de 800 clínicas veterinarias en 50 estados, resultando en la distribución de más de 10,000 jeringas de Spryng a nivel nacional desde su comercialización. Este éxito se alinea con el crecimiento proyectado del mercado de salud animal en los EE. UU., que se espera que alcance un valor de $11.3 mil millones para 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), 동물용 생물 의학 치료법을 제공하는 회사가 Bloomberg Television의 Sight & Sound Visionaries Series에 소개되었습니다. 이 에피소드는 동물의 골관절염 및 기타 근골격계 질환 관리를 위한 PetVivo의 대표 제품인 Spryng™와 OsteoCushion™ 기술를 강조했습니다. 이 프로그램은 9월 5일에 방영되었으며, 다양한 디지털 플랫폼을 통해 배포되어 폭넓은 청중에게 도달했습니다.
PetVivo의 CEO인 John Lai는 Spryng이 동물의 관절 건강에 미치는 변혁적인 영향을 강조했습니다. 이 회사는 Spryng이 50개 주의 800개 이상의 수의학 클리닉에서 사용되고 있다고 밝히며, 상용화 이후 전국적으로 10,000개 이상의 Spryng 주사기가 배포되었다고 보고했습니다. 이 성공은 2030년까지 113억 달러에 이를 것으로 예상되는 미국 동물 건강 시장의 성장 전망과 일치합니다.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), un fournisseur de thérapies biomédicales pour les animaux, a été présenté dans la série Visionaries de Sight & Sound sur Bloomberg Television. L'épisode a mis en avant Spryng™ avec la Technologie OsteoCushion™, le produit phare de PetVivo pour la gestion de l'ostéoarthrite et d'autres affections musculosquelettiques chez les animaux. Le programme a été diffusé le 5 septembre et distribué sur plusieurs plateformes numériques, atteignant un large public.
Le PDG de PetVivo, John Lai, a souligné l'impact transformateur de Spryng sur la santé articulaire des animaux. L'entreprise a réalisé des jalons significatifs, avec Spryng utilisé dans plus de 800 cliniques vétérinaires à travers 50 États, ce qui a entraîné la distribution de plus de 10 000 seringues de Spryng à l'échelle nationale depuis sa commercialisation. Ce succès est en adéquation avec la croissance projetée du marché de la santé animale aux États-Unis, qui devrait atteindre 11,3 milliards de dollars d'ici 2030.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), ein Anbieter von biomedizinischen Therapeutika für Tiere, wurde in der Visionaries Series von Sight & Sound auf Bloomberg Television vorgestellt. In dieser Episode wurde Spryng™ mit OsteoCushion™-Technologie hervorgehoben, das Flaggschiffprodukt von PetVivo zur Behandlung von Osteoarthritis und anderen muskuloskeletalen Erkrankungen bei Tieren. Die Sendung wurde am 5. September ausgestrahlt und über verschiedene digitale Plattformen verteilt, wodurch ein breites Publikum erreicht wurde.
Der CEO von PetVivo, John Lai, betonte die transformative Wirkung von Spryng auf die Gelenkgesundheit von Tieren. Das Unternehmen hat bedeutende Meilensteine erreicht, mit Spryng, das jetzt in über 800 Tierarztpraxen in 50 Bundesstaaten verwendet wird, was zur Verteilung von mehr als 10.000 Spryng-Spritzen im ganzen Land seit seiner Kommerzialisierung geführt hat. Dieser Erfolg steht im Einklang mit dem erwarteten Wachstum des Marktes für Tiergesundheit in den USA, das bis 2030 voraussichtlich 11,3 Milliarden Dollar erreichen wird.
- Spryng™ is now used in over 800 veterinary clinics across 50 states
- More than 10,000 Spryng syringes have been distributed nationwide
- Featured in Sight & Sound's Visionaries Series on Bloomberg Television, increasing product visibility
- U.S. animal health market projected to double to $11.3 billion by 2030, indicating strong growth potential
- None.
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, was recently featured in the Sight & Sound's Visionaries Series on Bloomberg Television.
The episode spotlighted PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary veterinary medical device that is transforming joint health for animals nationwide.
The unique injectable medical device has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions that contribute to animal lameness.
By mimicking the composition and function of natural joint cartilage and subsynovial tissue, SPRYNG™ offers a highly effective, drug-free option for veterinarians seeking long-term solutions that improve the quality of life for pets.
After airing on September 5, the Visionaries episode was distributed across New to the Street’s digital platforms, including its YouTube channel with 1.4 million subscribers, as well to its 300,000+ social media followers on Twitter, LinkedIn and Instagram.
The program provides insights for investors, stakeholders, and veterinarians into how PetVivo’s innovative solutions has positioned the company as a leader in the growing veterinary medical device industry.
Visionaries takes viewers inside PetVivo's Minnesota R&D laboratory, where PetVivo CEO, John Lai, along with leading scientists and veterinary experts, provide an in-depth exploration of the advanced science behind Spryng with OsteoCushion™ Technology and its transformative impact on animal joint health.
“Spryng™ has redefined how veterinarians approach joint health,” noted Lai, “making it increasingly important to bring our story to a greater national audience. By creating broader awareness of the use and multiple benefits of Spryng, we hope to accelerate the market adoption of this breakthrough product which has already made a major impact on the health and wellbeing of thousands of equine and companion animals.”
The Visionaries episode may be viewed in its entirety on the PetVivo website by clicking here.
PetVivo recently achieved major milestones with Spryng now used by more than 800 veterinary clinics across 50 states and this resulting in the distribution of more than 10,000 Spryng syringes nationwide since first commercialization.
The increasing success of Spryng™ also reflects the fast growing U.S. animal health market, which is projected to double to
For more information about PetVivo and Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
For more information, visit www.petvivo.com or contact Ron Both of CMA at (949) 432-7557 or submit your request here.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
FAQ
What is PetVivo's flagship product featured in the Bloomberg TV Visionaries series?
How many veterinary clinics are currently using Spryng™ according to the PetVivo press release?
What is the projected value of the U.S. animal health market by 2030, as mentioned in the PETV press release?
How many Spryng syringes has PetVivo (PETV) distributed since its commercialization?
